Stoke Therapeutics appoints Clare Kahn, Ph.D. to Board, increases size to ten

Stoke Therapeutics, Inc.

Board expanded to 10 directors; Kahn appointed as Class I director effective April 3, 2026.
Kahn receives $45k annual cash retainer and initial option for 30,782 shares (~$724k grant-date value).
Kahn will chair the R&D Committee and serve on the Nominating & Corporate Governance Committee.
Kahn brings 30+ years drug development and regulatory experience from X-VAX, Pfizer, and GSK.
Company is advancing Phase 3 study of zorevunersen for Dravet syndrome.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.